These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19768285)

  • 1. The troubled heparin issue in the Brazilian market and the search for solutions.
    Gomes WJ; Braile DM
    Rev Bras Cir Cardiovasc; 2009; 24(2):3-4. PubMed ID: 19768285
    [No Abstract]   [Full Text] [Related]  

  • 2. Heparin pharmacovigilance in Brazil.
    Junqueira DR; Viana TG; Peixoto ER; Barros FC; Carvalho Md; Perini E
    Rev Assoc Med Bras (1992); 2011; 57(3):322-6. PubMed ID: 21691698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin quality control in the Brazilian market: implications in the cardiovascular surgery.
    Melo EI; Pereira MS; Cunha RS; Sá MP; Mourão PA
    Rev Bras Cir Cardiovasc; 2008; 23(2):169-74. PubMed ID: 18820778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethylenediaminetetraacetic acid (EDTA) in heparin.
    Coyne E; Messmore HL; Walenga JM; Fareed J; Wehrmacher WH
    Thromb Res; 1998 Jun; 90(5):245-6. PubMed ID: 9694247
    [No Abstract]   [Full Text] [Related]  

  • 5. From crisis to opportunity: a perspective on the heparin crisis.
    Sasisekharan R; Shriver Z
    Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
    [No Abstract]   [Full Text] [Related]  

  • 6. The heparins: all a nephrologist should know.
    Hetzel GR; Sucker C
    Nephrol Dial Transplant; 2005 Oct; 20(10):2036-42. PubMed ID: 16030035
    [No Abstract]   [Full Text] [Related]  

  • 7. Tainted heparin crisis tested FDA's investigative skills.
    Lavine G
    Am J Health Syst Pharm; 2009 Feb; 66(3):210-1. PubMed ID: 19179633
    [No Abstract]   [Full Text] [Related]  

  • 8. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
    Lindahl U
    Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
    [No Abstract]   [Full Text] [Related]  

  • 9. A Brazilian perspective for the use of bovine heparin in open heart surgery.
    Gomes WJ; Leal JC; Braile DM; Guimarães JA; Lopes RD; Lima MA; Nader HB
    Int J Cardiol; 2016 Nov; 223():611-612. PubMed ID: 27561168
    [No Abstract]   [Full Text] [Related]  

  • 10. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in the characterization of heparin and its impurities.
    Larive CK
    Anal Bioanal Chem; 2011 Jan; 399(2):525-6. PubMed ID: 21116617
    [No Abstract]   [Full Text] [Related]  

  • 12. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
    McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
    J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from contaminated heparin.
    Dodd S; Besag FM
    Curr Drug Saf; 2009 Jan; 4(1):1. PubMed ID: 19149518
    [No Abstract]   [Full Text] [Related]  

  • 14. Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market.
    Beyer T; Matz M; Brinz D; Rädler O; Wolf B; Norwig J; Baumann K; Alban S; Holzgrabe U
    Eur J Pharm Sci; 2010 Jul; 40(4):297-304. PubMed ID: 20399266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins.
    Alban S; Lühn S; Schiemann S
    Anal Bioanal Chem; 2011 Jan; 399(2):681-90. PubMed ID: 20953779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in the USP heparin monograph and implications for clinicians.
    Smythe MA; Nutescu EA; Wittkowsky AK
    Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994
    [No Abstract]   [Full Text] [Related]  

  • 19. Heparin mimetics with anticoagulant activity.
    Nahain AA; Ignjatovic V; Monagle P; Tsanaktsidis J; Ferro V
    Med Res Rev; 2018 Sep; 38(5):1582-1613. PubMed ID: 29446104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anaphylactoid reactions associated with contaminated heparin from China].
    Montpas N; Désormeaux A; Keire D; Adam A
    Ann Pharm Fr; 2011 Sep; 69(5):258-64. PubMed ID: 21924126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.